244 related articles for article (PubMed ID: 11194468)
61. Aquaretic and hormonal effects of a vasopressin V(2) receptor antagonist after acute and long-term treatment in rats.
Lacour C; Galindo G; Canals F; Segondy D; Cazaubon C; Serradeil-Le Gal C; Roccon A; Nisato D
Eur J Pharmacol; 2000 Apr; 394(1):131-8. PubMed ID: 10771045
[TBL] [Abstract][Full Text] [Related]
62. 7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoyl-amino)benzoyl ]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): a potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist.
Kondo K; Ogawa H; Yamashita H; Miyamoto H; Tanaka M; Nakaya K; Kitano K; Yamamura Y; Nakamura S; Onogawa T; Mori T; Tominaga M
Bioorg Med Chem; 1999 Aug; 7(8):1743-54. PubMed ID: 10482466
[TBL] [Abstract][Full Text] [Related]
63. Response Prediction and Influence of Tolvaptan in Chronic Heart Failure Patients Considering the Interaction of the Renin-Angiotensin-Aldosterone System and Arginine Vasopressin.
Kadota M; Ise T; Yagi S; Iwase T; Akaike M; Ueno R; Kawabata Y; Hara T; Ogasawara K; Bando M; Bando S; Matsuura T; Yamaguchi K; Yamada H; Soeki T; Wakatsuki T; Sata M
Int Heart J; 2016 Jul; 57(4):461-5. PubMed ID: 27357439
[TBL] [Abstract][Full Text] [Related]
64. The syndrome of inappropriate antidiuretic hormone secretion.
Baylis PH
Int J Biochem Cell Biol; 2003 Nov; 35(11):1495-9. PubMed ID: 12824060
[TBL] [Abstract][Full Text] [Related]
65. The therapeutic efficacy of VP-343, a selective vasopressin V2 receptor antagonist, in the experimental SIADH rat model.
Naito A; Hasegawa H; Kurasawa T; Ohtake Y; Matsukawa H; Ezure Y; Tsuriya Y; Koike K; Shigenobu K
Biol Pharm Bull; 2000 Nov; 23(11):1323-7. PubMed ID: 11085360
[TBL] [Abstract][Full Text] [Related]
66. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
Schrier RW; Gross P; Gheorghiade M; Berl T; Verbalis JG; Czerwiec FS; Orlandi C;
N Engl J Med; 2006 Nov; 355(20):2099-112. PubMed ID: 17105757
[TBL] [Abstract][Full Text] [Related]
67. Tolvaptan for the management of syndrome of inappropriate antidiuretic hormone secretion: lessons learned in titration of dose.
Torres AC; Wickham EP; Biskobing DM
Endocr Pract; 2011; 17(4):e97-100. PubMed ID: 21613055
[TBL] [Abstract][Full Text] [Related]
68. Acute effects of vasopressin V2-receptor antagonist on kidney AQP2 expression and subcellular distribution.
Christensen BM; Marples D; Jensen UB; Frokiaer J; Sheikh-Hamad D; Knepper M; Nielsen S
Am J Physiol; 1998 Aug; 275(2):F285-97. PubMed ID: 9691020
[TBL] [Abstract][Full Text] [Related]
69. Up-regulation of renal adenylate cyclase-coupled vasopressin receptors after chronic administration of vasopressin antagonists to rats.
Caltabiano S; Kinter LB
J Pharmacol Exp Ther; 1991 Sep; 258(3):1046-54. PubMed ID: 1832462
[TBL] [Abstract][Full Text] [Related]
70. Low-dose tolvaptan PK/PD: comparison of patients with hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion to healthy adults.
Shoaf SE; Bricmont P; Dandurand A
Eur J Clin Pharmacol; 2017 Nov; 73(11):1399-1408. PubMed ID: 28803333
[TBL] [Abstract][Full Text] [Related]
71. Real-life experience of tolvaptan use in the treatment of severe hyponatraemia due to syndrome of inappropriate antidiuretic hormone secretion.
Tzoulis P; Waung JA; Bagkeris E; Carr H; Khoo B; Cohen M; Bouloux PM
Clin Endocrinol (Oxf); 2016 Apr; 84(4):620-6. PubMed ID: 26385871
[TBL] [Abstract][Full Text] [Related]
72. Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia.
Palm C; Pistrosch F; Herbrig K; Gross P
Am J Med; 2006 Jul; 119(7 Suppl 1):S87-92. PubMed ID: 16843091
[TBL] [Abstract][Full Text] [Related]
73. Efficacy and safety of intravenous OPC-61815 compared with oral tolvaptan in patients with congestive heart failure.
Sato N; Uno S; Kurita Y; Kim S;
ESC Heart Fail; 2022 Oct; 9(5):3275-3286. PubMed ID: 35794067
[TBL] [Abstract][Full Text] [Related]
74. Syndrome of inappropriate antidiuresis.
Kovacs L; Robertson GL
Endocrinol Metab Clin North Am; 1992 Dec; 21(4):859-75. PubMed ID: 1486879
[TBL] [Abstract][Full Text] [Related]
75. [The use of tolvaptan in a case of severe hyponatriemia in SIADH during meningitis].
Rollino C; Balbiano R; Caramello P; Roccatello D
G Ital Nefrol; 2013; 30(6):. PubMed ID: 24402662
[TBL] [Abstract][Full Text] [Related]
76. Vasopressin V2 receptor antagonists.
Wong LL; Verbalis JG
Cardiovasc Res; 2001 Aug; 51(3):391-402. PubMed ID: 11476729
[TBL] [Abstract][Full Text] [Related]
77. Pharmacokinetics, pharmacodynamics and safety of tolvaptan, a novel, oral, selective nonpeptide AVP V2-receptor antagonist: results of single- and multiple-dose studies in healthy Japanese male volunteers.
Kim SR; Hasunuma T; Sato O; Okada T; Kondo M; Azuma J
Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S5-17. PubMed ID: 22120090
[TBL] [Abstract][Full Text] [Related]
78. Improving care and outcomes of inpatients with syndrome of inappropriate antidiuresis (SIAD): a prospective intervention study of intensive endocrine input vs. routine care.
Tzoulis P; Carr H; Bagkeris E; Bouloux PM
Endocrine; 2017 Feb; 55(2):539-546. PubMed ID: 27837439
[TBL] [Abstract][Full Text] [Related]
79. Tolvaptan for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion.
Gargani L; Schmidt PH; Gheorghiade M
Expert Rev Cardiovasc Ther; 2011 Dec; 9(12):1505-13. PubMed ID: 22103869
[TBL] [Abstract][Full Text] [Related]
80. Codeine-induced syndrome of inappropriate antidiuretic hormone: case report.
Karahan S; Karagöz H; Erden A; Avcı D; Esmeray K
Balkan Med J; 2014 Mar; 31(1):107-9. PubMed ID: 25207179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
